Skip to main content

Table 1 Baseline characteristics of patients in placebo and silymarin groups

From: A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury

  Silymarin Placebo p-value
(N = 27) (N = 28)
Male (n, %) 10 (37.0) 12 (42.9) 0.785
Age (years) 56.0 (15, 78) 51.5 (21, 83) 0.721
BMI (kg/m2) 21.1 (14.1, 25.4) 21.0 (15.8, 27.0) 0.773
Dose of Isoniazid (mg/kg) 5.5 (4.0, 9.0) 5.7 (4.5, 7.7) 0.968
Dose of rifampicin (mg/kg) 10.4 (8.0, 14.0) 10.3 (9.0, 14.0) 0.965
Dose of pyrazinamide (mg/kg) 23.1 (18.6, 29.1) 23.8 (17.8, 58.0) 0.282
Dose of ethambutol (mg/kg) 18.5 (13.3, 24.9) 18.5 (12.7, 27.8) 0.859
Liver function tests
 ALT (IU/L) 29 (15, 66) 31 (11, 86) 0.639
 AST (IU/L) 20 (13, 106) 25.5 (14, 56) 0.087
 ALP (IU/L) 85 (37, 449) 89.5 (55, 508) 0.736
 GGT (IU/L) 42 (17, 430) 52.5 (14, 510) 0.443
 TP (g/L) 78.1 (50.5, 91.5) 76.0 (56.1, 99.4) 0.452
 Alb (g/L) 35.7 (23.0, 42.0) 33.0 (16.7, 43.8) 0.639
 TB (mg/dl) 0.5 (0.3, 1.9) 0.6 (0.2, 1.4) 0.285
 DB (mg/dl) 0.2 (0.1, 0.7) 0.3 (0.1, 5.0) 0.015
  1. BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; TP, total protein; Alb, albumin; TB, total bilirubin; DB, direct bilirubin
  2. Categorical variables reported as N (%). Continuous variables reported as median (interquartile range)